Lupin Launches Ajaduo M Forte, a Triple Fixed-Dose Combination of Empagliflozin, Linagliptin, and Metformin Extended Release (ER) MDTV Bureau31 March 2025 10:15 AM ISTGlobal pharmaceutical company Lupin Limited has announced the launch of Ajaduo M Forte, a novel triple fixed-dose combination (FDC) therapy for the...
USV Expands Diabetes Portfolio with Cost-Effective Liralin-EP in India Deeksha Bhandari22 March 2025 1:00 PM ISTUSV Pvt. Ltd., launches the Liralin EP a combination of Linagliptin & Empagliflozin at just Rs 12.90 per tablet for strengthening it's affordable...
Macleods Pharma Wins Legal Battle Over Linagliptin Patent Farhat Nasim21 Jan 2025 5:41 PM ISTNew Delhi: In a major setback to Boehringer Ingelheim, the Delhi High Court has upheld the maintainability of a revocation petition filed by...
Indian Pharma Market reaches Rs 19,083 crore in December, Check out top performing brands Farhat Nasim16 Jan 2025 7:43 PM ISTNew Delhi: The Indian Pharmaceutical Market (IPM) has experienced robust growth, reaching a market value of Rs 19,083 crore in December 2024. This...
Micro Labs Launches Linapride DM: Affordable Diabetes Treatment in India MD Brand Connect2 Sept 2024 12:48 PM ISTUncontrolled Diabetes has become a major challenge in today's Diabetes Management and it keeps raising the bar. As per the ICMR-INDIAB Study...
Dapagliflozin Linagliptin FDC Superior to Dapagliflozin Vildagliptin FDC in T2DM: Latest Indian Study Dr. Kamal Kant Kohli13 July 2024 11:00 AM ISTDapagliflozin and linagliptin fixed-dose combination (FDC) is superior to dapagliflozin and vildagliptin combination therapy in controlling Hba1c,...
Lupin secures USFDA tentative nod for Empagliflozin, Linagliptin and Metformin Hydrochloride ER tablets Ruchika Sharma10 July 2024 2:56 PM ISTMumbai: Global pharma major Lupin Limited has announced that it has received tentative approval from the United States Food and Drug...
Applicability of FDC of Linagliptin and Dapagliflozin in T2DM: EVERGREEN Case Report Summaries Dr Jeegar Dattani24 May 2024 11:00 AM ISTThe EVERGREEN webinar, designed to guide physicians regarding the care of people with diabetes, highlighted the clinical applicability of a...
Evergreen Talk Series: How can Safety and Tolerability of Linagliptin and Dapagliflozin benefit diverse T2DM population? MD Brand Connect25 March 2024 4:38 PM ISTPresenting the Evergreen Talk Series featuring Dr. Brij Mohan Makkar, a Senior Diabetologist and Obesity Specialist from Delhi, Dr Sameer I. Dani, an...
EVERGREEN Webinar: Clinical FAQs on T2DM Care, Addressed by Dr V Mohan Dr Jeegar Dattani6 March 2024 12:29 PM ISTThe Evergreen webinar addressed the clinical applicability of Linagliptin and Dapagliflozin in real-world clinical scenarios of type 2 diabetes....
Evergreen Talk Series: Combination of Linagliptin and Dapagliflozin in T2DM with multiple episodes of hypoglycemia MDTV Bureau21 Feb 2024 9:30 AM ISTPresenting the Evergreen Talk Series featuring Dr. Brij Mohan Makkar, a Senior Diabetologist and Obesity Specialist from Delhi, Dr Sameer I. Dani, an...
Top 10 Messages from Evergreen Webinar on Clinical Applicability of Linagliptin Dapagliflozin in Type 2 Diabetes, Addressed by Dr V Mohan Dr Jeegar Dattani12 Feb 2024 12:15 PM ISTDr. V. Mohan, M.D., FRCP (London, Edinburgh, Glasgow & Ireland), Ph.D., D.Sc. D.Sc (Hon. Causa), FNASc, FASc, FNA, FACE, FACP, FTWAS, MACP, FRSE....
